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Abstract. The gut endocrine cells control and regulate several 
functions of the gastrointestinal tract. They have been reported 
to be abnormal in irritable bowel syndrome (IBS), with altera-
tions occurring in several functions regulated by these cells. 
Furthermore, it has been established that gut endocrine cells 
interact with the gut lumen contents, particularly the nutrients. 
The present study was undertaken to establish whether the 
positive outcome of dietary guidance observed in patients 
suffering from IBS is associated with a change in gastric 
endocrine cells. A total of 46 patients with IBS participated 
in the present study, of which 14 completed all aspects. These 
patients included nine females and five males with a mean age 
of 34 years (range, 20-45 years). In the healthy control group, 
nine females and five males, with a mean age of 54 years 
(range 26-70 years) were selected. The patients and controls 
underwent gastroscopy with biopsy samples taken from the 
corpus and antrum of the stomach. Each patient attended 
three sessions that lasted ~45 min each, and received indi-
vidual guidance on their dietary management. The patients 
followed the diet prescribed for a minimum of three months, 
then further samples were taken using a method similar to 
that used for the initial biopsies. The biopsy samples were 
immunostained using the avidin-biotin complex method for 
chromogranin A (CgA) and quantified by computerized image 
analysis. The patients with IBS presented a low density of CgA 
compared with the controls. The density of CgA increased in 
these patients following dietary guidance and changes in food 
intake. The present observations emphasized the interaction 
between food intake and gut endocrine cells. The current study 
also suggests that the positive effects of dietary guidance may 
be attributed to changes in gut endocrine cell density.
Introduction
The gut endocrine cells constitute the largest endocrine organ in 
the body and consist of at least 15 types of endocrine cell (1-3). 
In addition to the endocrine mechanism of action, the biologi-
cally active substances secreted by these cells act locally on 
nearby structures through paracrine signaling (4,5). The endo-
crine cells are scattered among the epithelial cells that line the 
gut lumen. They have specialized microvilli that project into 
the lumen and function as sensors for the gut contents (mostly 
for nutrients), and they respond to luminal stimuli by releasing 
their hormones into the lamina propria (6-18).
The stomach comprises of four types of endocrine cells, 
which produce serotonin, somatostatin, ghrelin and gastrin (5). 
While serotonin and somatostatin-secreting cells are present 
in the corpus and the antrum of the stomach, ghrelin-secreting 
cells are localized to the corpus and gastrin-secreting G cells 
are located in the antrum (19).
Chromogranin A (CgA) is a common marker for gut 
endocrine cells (20-22). In a previous study, the density 
of CgA-secreting cells was observed to be abnormal in the 
stomach of patients with irritable bowel syndrome (IBS) (23). 
Further studies have demonstrated that the densities of all the 
gastric endocrine cells are affected in patients with IBS (24).
Dietary management guidance given to patients with 
IBS has been indicated to reduce symptoms and improve 
the quality of life (25,26). The endocrine cells of the gut are 
stimulated by the contents of the gut lumen, particularly nutri-
ents (27,28). Therefore, the present study was undertaken to 
investigate whether the positive effects of dietary management 
guidance observed in patients with IBS are associated with 
changes in the densities of endocrine cells in the stomachs of 
these patients.
Materials and methods
Patients and controls. Patients that were referred to our 
clinic  at Stord Helse-Fonna Hospital (Stord, Norway) and 
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fulfilled the Rome‑III criteria (29) for IBS diagnosis were 
considered for inclusion in the current study. Females and 
males aged between 18 and 70 years were selected. Pregnant 
or lactating females, and patients with organic gastrointes-
tinal or other systemic diseases, a history of drug abuse, or 
serious psychiatric disturbances were excluded. Patients that 
had undergone previous abdominal surgery, with the excep-
tion of appendectomy, caesarean and hysterectomy, were also 
excluded.
The control group included healthy subjects that underwent 
gastroscopy due to the following reasons: Gastrointestinal 
bleeding, where the source of bleeding was identified as hemor-
rhoids (n=3) or angiodysplasia (n=1); and health concerns as a 
result of diagnosis of a family member with gastrointestinal 
cancer (n=10). The control group consisted of nine females and 
five males with a mean age of 54 years (range, 26‑70 years).
The present study was performed in accordance with the 
year 2000 edition of the Declaration of Helsinki and approved 
by the Regional Committee for Medical Research Ethics of 
West Norway. All patients submitted oral and written consent.
Study design. A total of 46 patients participated in the present 
study, including 35 females and 11 males with a mean age of 
35 years (range, 18‑69 years). The patients were subjected 
to physical examinations and blood tests in order to exclude 
inflammation, infection or other organic diseases. Additionally, 
these patients underwent colonoscopy with segmental biopsy 
samples to exclude microscopic colitis. Each patient was 
scheduled for three sessions of individual dietary manage-
ment guidance with an experienced nurse, lasting ~45 min 
each. These sessions were conducted with intervals of at least 
2 weeks. The patients underwent gastroscopy prior to the first 
session and 3-9 months (median 4 months) following the third 
session of dietary management guidance.
Individual dietary management guidance. In the sessions, 
information was provided orally using charts, in addition to 
written illustrated information. The initial session included 
general information regarding IBS and the importance of 
regular and healthy eating habits. The diets that worsen IBS 
symptoms, such as insoluble dietary fibers and the poorly 
absorbed highly fermentable oligosaccharides, disaccharides, 
monosaccharaides and polyols (FODMAPs) were explained. 
The patients were encouraged to consume dairy products 
daily and were informed that milk and dairy products do 
not provoke IBS symptoms. The patients were required to 
write a diary, in which they recorded their daily food and 
drink intake, the frequency and degree of abdominal pain, 
abdominal distension, stool frequency and consistency, for 
2 weeks. In addition the patients were asked to test a protein-, 
fat- or carbohydrate-rich/poor diet. In the second session, the 
information given in the first session was briefly repeated. 
The nurse and the patient discussed the symptom-triggering 
items based on the information noted in the patient's diary. The 
patients were then advised to alter the proportions of protein, 
fat and carbohydrate, avoid items rich in FODMAPs and 
insoluble fibers, and consume vegetables and fruits containing 
less FODMAPs and insoluble fibers. During the last session 
the patients informed the nurse of their experience of dietary 
management. The nurse, along with the patient, designed a 
suitable diet, which was strictly followed by the patient until 
the end-point of the study.
Gastroscopy, tissue sampling, histopathology and immuno-
histochemistry. Following an overnight fast, the patients and 
control subjects underwent standard gastroscopy. Four biopsy 
samples were taken from the corpus (major curvature) and 
another four biopsy samples from the antrum of the stomach. 
Furthermore, four biopsy samples were taken from the 
duodenum in order to exclude celiac disease.
The biopsy samples were fixed in 4% buffered parafor-
maldehyde overnight, embedded in paraffin wax, and were 
then cut into 5-µm sections. Biopsy samples from the stomach 
and duodenum underwent histopathological examinations. 
Biopsy samples from the corpus and antrum were stained 
with hematoxylin and eosin and immunostained with the 
avidin-biotin complex method using a Vectastain ABC kit 
(Vector laboratories, Burlingame, CA, USA) and the chro-
mogen 3,3'‑diaminobenzidine peroxidase substrate (DAB) kit 
(Vector Laboratories) as described previously (30). Briefly, the 
sections were incubated for 2 h at room temperature with a 
monoclonal mouse anti‑N‑terminal of purified CgA primary 
antibody (code no. M869; Dako, Glostrup, Denmark) diluted 
1:1,000. Following incubation, the sections were washed in 
phosphate-buffered saline (PBS; pH 7.4) and incubated for 
30 min at room temperature with biotinylated swine anti-mouse 
IgG diluted to 1:200 (Dako). The slides were washed with 
PBS, and incubated for 30 min with avidin-biotin-peroxidase 
complex diluted 1:100, and then submerged in 3,3'-diamino-
benzidine, followed by counterstaining with hematoxylin.
Computerized image analysis. The density of chromogranin A 
in the corpus and antrum of patients with IBS and controls was 
measured using Olympus Cell^D software, Olympus, (Tokyo, 
Japan). The number of chromogranin A positive cells and the 
area of the epithelial cells were measured in 10 randomly 
selected fields, magnification, x40. At this magnification each 
field represents a tissue area of 0.14 mm2. The chromogranin 
A cell density was expressed as the number of cells/mm2 of 
the epithelium. All quantification was conducted by the same 
scientist (Dr Tarek Mazzawi), who was blinded to the identity 
of the sections.
Statistical analysis. The paired t-test was used to compare the 
results of patients prior to and following dietary guidance with 
results in the control subjects. The data are presented as the 
mean ± standard error. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Patients and controls. A total of 25 patients withdrew their 
consent at various stages of the study. The majority of these 
were due to a lack of motivation when their symptoms 
improved following dietary guidance and/or unwillingness 
to undergo a second gastroscopy. Two patients were excluded 
due to non-compliance. Five patients were excluded as they 
were diagnosed with celiac disease (n=2), lupus (n=1), became 
pregnant (n=1) or moved abroad (n=1) during the course of 
the study. Thus, fourteen patients completed the study. These 
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patients consisted of nine females and five males with a mean 
age of 34 years (range, 20-45 years). Biopsies from one female 
patient were obtained only from the antrum.
Gastroscopy, histopathology and immunohistochemistry. 
The macroscopic appearance of the esophagus, stomach and 
duodenum was normal in patients and controls. Histopathological 
examination displayed normal histology of the stomach and 
duodenum in patients and controls. CgA immunoreactive cells 
were identified in the mucosa of the stomach in the two groups. 
These cells were either basket‑ or flask‑shaped, and a number of 
them had a long basal cytoplasmic process.
Computerized image analyses
Corpus. The mean density of CgA-secreting cells in controls 
was 147.9 cells/mm2 (95% CI: 113.8‑182). The densities of the 
CgA-secreting cells in patients with IBS prior to and following 
dietary guidance were 62.6±9.3 and 102.3±14.3 cells/mm2, 
respectively (Figs. 1 and 2). The paired t-test indicated a 
significant increase in the densities of CgA‑secreting cells in 
IBS patients following dietary guidance (P=0.0064).
Antrum. The mean density of the CgA-secreting cells in 
the antrum was 87.7 cells/mm2 (95% CI: 43.8‑131.7). The 
densities of the CgA-secreting cells in patients with IBS 
prior to and following dietary guidance was 28.5±6.5 and 
46.5±11.1 cells/mm2, respectively (Figs. 3 and 4). No signifi-
cant difference in the densities of CgA-secreting cells was 
detected in IBS patients prior to and following dietary guid-
ance (P=0.2).
Discussion
Patients with IBS are recognized to have a high dropout rate in 
clinical studies (26,31). The design of the present study involved 
invasive gastroscopy examinations, and adhering to a strict diet 
for a minimum of 3 months. This design may have contributed 
to the high rate of dropout in addition to the non-compliance 
experienced in the current study. Additionally, exclusions 
Figure 1. CgA cell density in the corpus of patients with IBS before and 
after receiving dietary management guidance. The dashed lines (a and c) 
represent the upper and lower limits of the 95% confidence interval of the 
mean in the control subjects. Line b represents the mean cell density of 
CgA in control subjects. **P<0.01. CgA, chromogranin A; IBS, irritable 
bowel syndrome.
Figure 2. CgA immunoreactive cells in the corpus of (A) a control subject and 
an IBS patient (B) prior to and (C) following guidance on dietary manage-
ment. The density of CgA cells prior to diet management is lower in IBS 
patients compared with controls, whereas the density in patients with IBS 
is almost the same as in controls following diet management. CgA, chromo-
granin A; IBS, irritable bowel syndrome.
MAZZAWI et al:  DIET AND GUT ENDOCRINE CELLS IN IBS 2325
due to unexpected events occurring during the study, such as 
pregnancy, moving abroad or other diagnoses contributed to 
the low number of patients that fulfilled the criteria required 
to complete the study. Regardless of the small sample size, the 
present study indicated a clear effect on gastric endocrine cell 
density following changes in diet.
The density of CgA-secreting cells in the stomach (in 
the corpus and antrum) was abnormal in IBS patients in the 
present study prior to receiving dietary guidance, similar to 
results reported in a previous study (23). Following dietary 
guidance and a change of diet, the density of CgA-secreting 
cells significantly increased in the corpus towards the values 
observed in healthy controls. With regards to the antrum, these 
changes were also observed but did not reach a significant 
level. This increase demonstrates that changes in food intake 
via dietary guidance alters the density of the total gastric 
endocrine cells towards a normal level.
In a previous study on the same cohort of patients inves-
tigated in the present study (25), a similar dietary program 
resulted in a reduction of the symptoms and an improvement 
in the quality of life of the patients. The observation in the 
current study, that dietary changes can promote a density of 
endocrine cells that is more similar to that of healthy patients, 
suggests that these changes may be one of the causes for the 
amelioration of symptoms and consequently the improvement 
in the quality of life in the patients with IBS of the previous 
study. The findings of the present study support the hypothesis 
that gut endocrine cells are important in the pathogenesis of 
IBS (32,33).
Gut endocrine cells have microvilli extending to the lumen 
that act as sensors for the contents of the gut and respond to the 
luminal stimuli (32). It has been reported that each intestinal 
crypt contains 4-6 pluripotent cells that differentiate through 
a series of cellular precursors into all epithelial cell types, 
including the endocrine cells (34-43). This differentiation is 
rapid and takes 2-4 days (44,45).
In conclusion, the current study demonstrated that the 
change in diet with the consequent change in the contents of 
the gut lumen may be the cause of alterations to the differentia-
Figure 3. CgA cell density in the antrum of patients with IBS before and 
after receiving dietary management guidance. The dashed lines (a and c) 
represent the upper and lower limits of the 95% confidence interval of 
the mean in the control subjects. Line b represents the mean cell density 
of CgA in control subjects. CgA, chromogranin A; IBS, irritable bowel 
syndrome.
Figure 4. CgA immunoreactive cells in the antrum of (A) a control subject 
and an IBS patient (B) prior to and (C) following guidance on dietary man-
agement. The density of CgA cells prior to diet management is lower in IBS 
patients compared with controls, whereas the density in patients with IBS is 
almost the same as in controls following diet management. CgA, chromo-
granin A; IBS, irritable bowel syndrome.
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tion of endocrine cells observed in patients with IBS, resulting 
in an increase in the density of endocrine cells.
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